Effect of cell origin and timing of delivery for stem cell-based bone tissue engineering using biologically functionalized hydrogels

Tissue Engineering - Part A

Volumn 21, Issue 1-2, 2015, Pages 156-165

  Dosier, Christopher R ^a   Uhrig, Brent A ^a   Willett, Nick J ^a   Krishnan, Laxminarayanan ^a   Li, Mon Tzu Alice ^a   Stevens, Hazel Y ^a   Schwartz, Zvi ^a,b   Boyan, Barbara D ^a,b   Guldberg, Robert E ^a  

^a GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE; CELL CULTURE; CELL ENGINEERING; CELLS; CYTOLOGY; DEFECTS; STEM CELLS; TISSUE; TISSUE ENGINEERING;

BONE MARROW-DERIVED MESENCHYMAL STEM CELLS; BONE MORPHOGENETIC PROTEIN-2; BONE TISSUE ENGINEERING; CURRENT TREATMENTS; DELIVERY TECHNIQUES; MINERALIZED TISSUE; SUBCUTANEOUS IMPLANTS; THERAPEUTIC DELIVERY;

HYDROGELS;

ALGINIC ACID; ARGINYLGLYCYLASPARTIC ACID; BONE MORPHOGENETIC PROTEIN 2; CD68 ANTIGEN; 4',6 DIAMIDINO 2 PHENYLINDOLE; CD68 ANTIGEN, HUMAN; DIFFERENTIATION ANTIGEN; GLUCURONIC ACID; GREEN FLUORESCENT PROTEIN; HEXURONIC ACID; HYDROGEL; INDOLE DERIVATIVE; LEUKOCYTE ANTIGEN;

ADIPOSE DERIVED STEM CELL; ADULT STEM CELL; ALGINATE HYDROGEL; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE DEFECT; BONE MARROW DERIVED MESENCHYMAL STEM CELL; BONE MASS; BONE MINERALIZATION; BONE REGENERATION; BONE REMODELING; CELL COUNT; CELL INFILTRATION; CELL INVASION; CELL PROLIFERATION; CELL SCREENING; CELL VIABILITY; COMPARATIVE STUDY; COMPUTED TOMOGRAPHY SCANNER; CONTROLLED STUDY; DIAPHYSIS; DNA CONTENT; FEMALE; FRACTURE HEALING; HISTOLOGY; HOST CELL; HYDROGEL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; MICRO-COMPUTED TOMOGRAPHY; NONHUMAN; OSSIFICATION; PRIORITY JOURNAL; RAT; TISSUE ENGINEERING; X RAY SYSTEM; ADIPOSE TISSUE; ANIMAL; BONE; BONE DEVELOPMENT; CELL SURVIVAL; CYTOLOGY; DRUG EFFECTS; IMAGE PROCESSING; IMPLANT; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY; PHARMACOLOGY; PHYSIOLOGY; PROCEDURES; SPRAGUE DAWLEY RAT; SUBCUTANEOUS TISSUE; TIME FACTOR;

ADIPOSE TISSUE; ALGINATES; ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BONE AND BONES; CALCIFICATION, PHYSIOLOGIC; CELL SURVIVAL; DIAPHYSES; GLUCURONIC ACID; GREEN FLUORESCENT PROTEINS; HEXURONIC ACIDS; HYDROGELS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; IMPLANTS, EXPERIMENTAL; INDOLES; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; OSTEOGENESIS; RATS, SPRAGUE-DAWLEY; SUBCUTANEOUS TISSUE; TIME FACTORS; TISSUE ENGINEERING; X-RAY MICROTOMOGRAPHY;

EID: 84921355116     PISSN: 19373341     EISSN: 1937335X     Source Type: Journal    
DOI: 10.1089/ten.tea.2014.0057     Document Type: Article

References (53)

1. Bruder, S.P., and Fox, B.S. Tissue engineering of bone. Cell based strategies. Clin Orthop Relat Res 367 Suppl, S68, 1999.
2. Laurencin, C., Khan, Y., and El-Amin, S.F. Bone graft substitutes. Exp Rev Med Devices 3, 49, 2006.
3. Nandi, S.K., et al. Orthopaedic applications of bone graft & graft substitutes: a review. Indian J Med Res 132, 15, 2010.
4. Bauer, T.W., and Muschler, G.F. Bone graft materials: an overview of the basic science. Clin Orthop Relat Res 371, 10, 2000.
5. Wheeler, D.L., and Enneking, W.F. Allograft bone decreases in strength in vivo over time. Clin Orthop Relat Res 435, 36, 2005.
6. Sorger, J.I., et al. Allograft fractures revisited. Clin Orthop Relat Res 382, 66, 2001.
7. Babiker, H. Bone graft materials in fixation of orthopaedic implants in sheep. Danish Med J 60, B4680, 2013.
8. Damien, C.J., and Parsons, J.R. Bone graft and bone graft substitutes: a review of current technology and applications. J Appl Biomater 2, 187, 1991.
9. Giannoudis, P.V., Dinopoulos, H., and Tsiridis, E. Bone substitutes: an update. Injury 36, S20, 2005.
10. Nauth, A., et al. Managing bone defects. J Orthop Trauma 25, 462, 2011.
11. Giannoudis, P.V., et al. Masquelet technique for the treatment of bone defects: tips-tricks and future directions. Injury 42, 591, 2011.
12. Masquelet, A.C. Muscle reconstruction in reconstructive surgery: soft tissue repair and long bone reconstruction. Langenbecks Arch Surg 388, 344, 2003.
13. Klaue, K., et al. Bone regeneration in long-bone defects: tissue compartmentalisation? In vivo study on bone defects in sheep. Injury 40, S95, 2009.
14. Stafford, P.R., and Norris, B.L. Reamer-irrigator-Aspirator bone graft and bi Masquelet technique for segmental bone defect nonunions: a review of 25 cases. Injury 41 Suppl 2, S72, 2010.
15. Pelissier, P., et al. Induced membranes secrete growth factors including vascular and osteoinductive factors and could stimulate bone regeneration. J Orthop Res 22, 73, 2004.
16. Kolambkar, Y.M., et al. Spatiotemporal delivery of bone morphogenetic protein enhances functional repair of seg-mental bone defects. Bone 49, 485, 2011.
17. Boerckel, J.D., et al. Effects of protein dose and delivery system on BMP-mediated bone regeneration. Biomaterials 32, 5241, 2011.
18. Razzouk, S., and Sarkis, R. BMP-2: biological challenges to its clinical use. N Y State Dent J 78, 37, 2011.
19. Blum, J.S., et al. In vivo evaluation of gene therapy vectors in ex vivo-derived marrow stromal cells for bone regeneration in a rat critical-size calvarial defect model. Hum Gene Ther 14, 1689, 2003.
20. Caplan, A.I. Mesenchymal stem cells. J Orthop Res 9, 641, 1991.
21. Cowan, C.M., et al. Adipose-derived adult stromal cells heal critical-size mouse calvarial defects. Nat Biotechnol 22, 560, 2004.
22. Dupont, K.M., et al. Human stem cell delivery for treatment of large segmental bone defects. Proc Natil Acad Sci USA 107, 3305, 2010.
23. Friedenstein, A.J., Piatetzky, S. II, and Petrakova, K.V. Osteogenesis in transplants of bone marrow cells. J Em-bryol Exp Morphol 16, 381, 1966.
24. Gan, Y., et al. The clinical use of enriched bone marrow stem cells combined with porous beta-tricalcium phosphate in posterior spinal fusion. Biomaterials 29, 3973, 2008.
25. Gimble, J., and Guilak, F. Adipose-derived adult stem cells: isolation, characterization, and differentiation potential. Cytotherapy 5, 362, 2003.
26. Hasharoni, A., et al. Murine spinal fusion induced by engineered mesenchymal stem cells that conditionally express bone morphogenetic protein-2. J Neurosurg Spine 3, 47, 2005.
27. Hicok, K.C., et al. Human adipose-derived adult stem cells produce osteoid in vivo. Tissue Eng 10, 371, 2004.
28. Niemeyer, P., et al. Comparison of mesenchymal stem cells from bone marrow and adipose tissue for bone regeneration in a critical size defect of the sheep tibia and the influence of platelet-rich plasma. Biomaterials 31, 3572, 2010.
29. Zuk, P.A., et al. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 13, 4279, 2002.
30. Zuk, P.A., et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 7, 211, 2001.
31. Alsberg, E., et al. Cell-interactive alginate hydrogels for bone tissue engineering. J Dent Res 80, 2025, 2001.
32. Alsberg, E., et al. Regulating bone formation via controlled scaffold degradation. J Dent Res 82, 903, 2003.
33. Farrell, E., et al. A comparison of the osteogenic potential of adult rat mesenchymal stem cells cultured in 2-D and on 3-D collagen glycosaminoglycan scaffolds. Technol Health Care 15, 19, 2007.
34. Kolambkar, Y.M., et al. An alginate-based hybrid system for growth factor delivery in the functional repair of large bone defects. Biomaterials 32, 65, 2011.
35. Oest, M.E., et al. Quantitative assessment of scaffold and growth factor-mediated repair of critically sized bone defects. J Orthop Res 25, 941, 2007.
36. Diab, T., et al. A silk hydrogel-based delivery system of bone morphogenetic protein for the treatment of large bone defects. J Mech Behav Biomed Mater 11, 123, 2012.
37. Willett, N.J., et al. Attenuated human bone morphogenetic protein-2-mediated bone regeneration in a rat model of composite bone and muscle injury. Tissue Eng Part C Methods 19, 316, 2013.
38. Duvall, C.L., et al. Impaired angiogenesis, early callus formation, and late stage remodeling in fracture healing of osteopontin-deficient mice. J Bone Miner Res 22, 286, 2007.
39. Street, J., et al. Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad Sci USA 99, 9656, 2002.
40. Fraser, J.K., et al. Fat tissue: an underappreciated source of stem cells for biotechnology. Trends Biotechnol 24, 150, 2006.
41. Nakagami, H., et al. Adipose tissue-derived stromal cells as a novel option for regenerative cell therapy. J Atheroscler Thromb 13, 77, 2006.
42. Dudas, J.R., et al. The osteogenic potential of adipose-derived stem cells for the repair of rabbit calvarial defects. Ann Plast Surg 56, 543, 2006.
43. Knippenberg, M., et al. Osteogenesis versus chondrogen-esis by BMP-2 and BMP-7 in adipose stem cells. Biochem Biophys Res Commun 342, 902, 2006.
44. Kawabori, M., et al. Timing and cell dose determine therapeutic effects of bone marrow stromal cell transplantation in rat model of cerebral infarct. Neuropathology 33, 140, 2012.
45. Kawabori, M., et al. Intracerebral, but not intravenous, transplantation of bone marrow stromal cells enhances functional recovery in rat cerebral infarct: an optical imaging study. Neuropathology 32, 217, 2012.
46. Traverse, J.H., et al. Rationale and design for TIME: a phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction. Am Heart J 158, 356, 2009.
47. Schachinger, V., et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 355, 1210, 2006.
48. Schachinger, V., et al. Improved clinical outcome after in-tracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Eur Heart J 27, 2775, 2006.
49. Traverse, J.H., et al. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function. JAMA 306, 2110, 2011.
50. Traverse, J.H., et al. LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction. Tex Heart Inst J 37, 412, 2010.
51. Liu, R., et al. Myogenic progenitors contribute to open but not closed fracture repair. BMC Musculoskelet Disord 12, 288, 2011.
52. Shapiro, F., Bone development and its relation to fracture repair. The role of mesenchymal osteoblasts and surface osteoblasts. Eur Cell Mater 15, 53, 2008.
53. Allen, A.B., et al. In vivo bioluminescent tracking of mesenchymal stem cells within large hydrogel constructs. Tissue Eng Part C Methods 2014 [Epub ahead of print]; DOI:10.1089/ten.tec.2013.0587.